Market Overview

UPDATE: Piper Jaffray Reiterates Overweight Rating, Raises PT on Isis Pharmaceuticals

Related ISIS
Defense Stock Roundup: Textron Reports Impressive Q2 Earnings, Lockheed Wins Indian Super Hercules Contract
Isis Pharmaceuticals Initiates Phase 2 Study Of ISIS-APO(a) Rx In Patients With High Lp(a)

In a report published Wednesday, Piper Jaffray & Co. reiterated its Overweight rating on Isis Pharmaceuticals (NASDAQ: ISIS), and raised its price target from $15.00 to $18.00.

Piper Jaffray noted, “ISIS is the leading antisense company with a rich pipeline of drugs in development. The primary driver for ISIS shares remains KYNAMRO with European approval this year and a January 29, 2013 PDUFA date. While ISIS shares have risen considerably since May 1st, we look for continued upside driven by KYNAMRO approval, clinical data read-outs and new partnerships. ISIS remains a Top Pick for 2H:12.”

Isis Pharmaceuticals closed Tuesday at $13.74.

Posted-In: Piper Jaffray & Co.Analyst Color Price Target Analyst Ratings

 

Most Popular

Related Articles (ISIS)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free